Literature DB >> 7747721

Disappearance of uremia due to heroin-associated nephropathy.

E A Friedman1, T K Tao.   

Abstract

Heroin-associated nephropathy (HAN), a complication of intravenous heroin abuse, was initially recognized at Kings County Hospital in Brooklyn, NY, in the early 1970s. Our recent experience indicates that after a steady incidence of new cases of HAN throughout the mid-1980s, a sharp decrease in incidence of new cases occurred starting in 1989. We sought to explore possible explanations for what amounts to disappearance of a previously prevalent disease. By means of retrospective analysis of a hospital-specific registry of new cases of end-stage renal disease (ESRD) at Kings County Hospital in Brooklyn, incidence curves from 1981 through 1993 for new cases of HAN, diabetes-induced renal disease, and human immunodeficiency virus-associated nephropathy were constructed. From hospital computer records, the number of admissions directly related to opioid abuse were extracted and charted. Unpublished surveillance records of the New York State Office of Alcoholism and Substance Abuse Services as well as reports from the New York City Department of Health, Office of AIDS Surveillance and the US Department of Justice Drug Enforcement Administration were used to determine the pattern of change in the prevalence of heroin abuse. Additionally, we used analysis of "street" heroin by the Drug Enforcement Administration to draw curves detailing drug cost and purity in New York City. There were no new cases of ESRD due to HAN for the years 1991 through 1993. The rates for new cases of ESRD due to diabetes and hypertension remained relatively constant throughout this interval.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7747721     DOI: 10.1016/0272-6386(95)90543-x

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

Review 1.  APOL1 and kidney cell function.

Authors:  Vinod Kumar; Pravin C Singhal
Journal:  Am J Physiol Renal Physiol       Date:  2019-06-26

2.  Clinical Significance of IgM and C3 Glomerular Deposition in Primary Focal Segmental Glomerulosclerosis.

Authors:  Yi-Miao Zhang; Qiu-Hua Gu; Jing Huang; Zhen Qu; Xin Wang; Li-Qiang Meng; Fang Wang; Gang Liu; Zhao Cui; Ming-Hui Zhao
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-23       Impact factor: 8.237

3.  Risk factors for proteinuria in HIV-infected and -uninfected Hispanic drug users.

Authors:  Martin S Rhee; Christopher H Schmid; Lesley A Stevens; Janet E Forrester
Journal:  Am J Kidney Dis       Date:  2008-06-24       Impact factor: 8.860

4.  Modulation of renin angiotensin system predominantly alters sclerotic phenotype of glomeruli in HIVAN.

Authors:  Andrei Plagov; Xiqian Lan; Partab Rai; Dileep Kumar; Rivka Lederman; Shabina Rehman; Ashwani Malhotra; Guohua Ding; Praveen N Chander; Pravin C Singhal
Journal:  Histol Histopathol       Date:  2014-06-03       Impact factor: 2.303

Review 5.  Apolipoprotein L1 (APOL1) Variants (Vs) a possible link between Heroin-associated Nephropathy (HAN) and HIV-associated Nephropathy (HIVAN).

Authors:  Xiqian Lan; T K S Rao; Praveen N Chander; Karl Skorecki; Pravin C Singhal
Journal:  Front Microbiol       Date:  2015-06-09       Impact factor: 5.640

Review 6.  Secondary Focal Segmental Glomerulosclerosis: From Podocyte Injury to Glomerulosclerosis.

Authors:  Jae Seok Kim; Byoung Geun Han; Seung Ok Choi; Seung-Kuy Cha
Journal:  Biomed Res Int       Date:  2016-03-21       Impact factor: 3.411

Review 7.  What Do We Know about Opioids and the Kidney?

Authors:  Mary Mallappallil; Jacob Sabu; Eli A Friedman; Moro Salifu
Journal:  Int J Mol Sci       Date:  2017-01-22       Impact factor: 5.923

Review 8.  Systematic review of nephrotoxicity of drugs of abuse, 2005-2016.

Authors:  Kanaan Mansoor; Murad Kheetan; Saba Shahnawaz; Anna P Shapiro; Eva Patton-Tackett; Larry Dial; Gary Rankin; Prasanna Santhanam; Antonios H Tzamaloukas; Tibor Nadasdy; Joseph I Shapiro; Zeid J Khitan
Journal:  BMC Nephrol       Date:  2017-12-29       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.